Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma
KCT0003913Phase 2Completed
- Sponsor
- Boryung
- Start
- Jan 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, paclitaxel, carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Boryung. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on KCT0003913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003913.